Loading
NASDAQHealthcareMedical - Devices
Latest quote
$2.23
−$0.07 · -3.04%
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Previous close
$2.23
−$0.07 · -3.04%
Regular session · ET · Market data may be delayed.
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Day range
Current $2.23
52-week range
Current $2.23
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Sell
Trim exposure — unfavorable risk-reward
Valuation
31
Expensive
Sentiment
52
Mixed
Risk
88
Extreme Risk
Momentum
17
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Day range
Current $2.23
52-week range
Current $2.23
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 4.22M USD | 3.05M USD | 3.11M USD | 1.26M USD | — |
| Cost of goods sold | 2.17M USD | 1.81M USD | 1.69M USD | 930.2K USD | — |
| Gross profit | 2.05M USD | 1.25M USD | 1.43M USD | 326.67K USD | — |
| Research and development | 3.37M USD | 2.4M USD | 1.67M USD | 507.42K USD | 3.85M USD |
| Selling, general, and administrative | 10.5M USD | 8.88M USD | 9.26M USD | 8.03M USD | 4.92M USD |
| Operating expenses | 14.66M USD | 11.89M USD | 11.71M USD | 12.92M USD | 8.34M USD |
| Interest income | 110.33K USD | 101.52K USD | 84.82K USD | 9.68K USD | 14.43K USD |
| Interest expense | 10.74K USD | 60.89K USD | 167.14K USD | 223.53K USD | 7.54K USD |
| Depreciation and amortization | 1.16M USD | 970.12K USD | 974.36K USD | 966.73K USD | — |
| Operating income | −12.61M USD | −10.64M USD | −10.28M USD | −12.6M USD | −8.34M USD |
| Net income | −12.43M USD | −10.57M USD | −10.16M USD | −10.63M USD | −8.31M USD |
Company facts updated Sep 5, 2026.
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
